Home
NewsNewsThe Florida Supreme Court has clarified that its statute on reproductive technology does not apply to At-Home Artificial Insemination.
The Florida Supreme Court went on to rule recently that a man who went on to offer his sperm to a couple for at-home artificial insemination did not automatically give up his paternal rights.
The 4-3 decision went on to determine that the previous legislation that surrounds artificial insemination only went on to apply to the use of assisted reproductive technology - ART, which is defined as procreative procedures involving the laboratory handling when it comes to human eggs or preembryos, says the ruling.
Apparently, the case in question goes on to involve Angel Rivera, who is a Florida man who went on to give his sperm to Ashley Brito and Jennifer Salas for use with an at-home artificial insemination kit.
Brito apparently gave birth to the child, and she, along with Salas, was listed as the parent of the child on the birth certificate. The couple went on to raise the child together for more than a year before separating, as per the ruling. Rivera then went on to file a petition in circuit court seeking to be recognized as the legal father of the child.
The court, however, denied this petition on the grounds that he went on to give up his paternal rights as per section 742.14, which states that the donor of any egg, sperm, or even pre-embryo, other than the commissioning couple or a father who has gone on to execute a preplanned adoption agreement as per s. 63.213, shall not be subject to the maternal or paternal rights and even obligations with regard to the donation or the resulting children.
In the decision made by the court, it said Rivera happened to be a sperm donor who had not met either of the two exceptions of relinquishment of the statute. Moreover, the court further said that the artificial insemination procedure, since it was not carried out in a clinical setting, does not alter the applicability of the statute.
Notably, the Second District also affirmed the ruling made by the circuit court.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
